Reevaluation of acromegalic patients in long-term remission according to newly proposed consensus criteria for control of disease

Elisa Verrua, Emanuele Ferrante, Marcello Filopanti, Elena Malchiodi, Elisa Sala, Claudia Giavoli, Maura Arosio, Andrea Gerardo Lania, Cristina Lucia Ronchi, Giovanna Mantovani, Paolo Beck-Peccoz, Anna Spada

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Acromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likely that a percentage of patients previously considered as cured might present postglucose GH nadir levels not adequately suppressed, with potential implications on management. This study explored GH secretion, as well as hormonal, clinical, neuroradiological, metabolic, and comorbid profile in a cohort of 40 acromegalic patients considered cured on the basis of the previous guidelines after a mean follow-up period of 17.2 years from remission, in order to assess the impact of the current criteria. At the last follow-up visit, in the presence of normal IGF-I concentrations, postglucose GH nadir was over 0.4 g/L in 11 patients (Group A) and below 0.4 g/L in 29 patients (Group B); moreover, Group A showed higher basal GH levels than Group B, whereas a significant decline of both GH and postglucose GH nadir levels during the follow-up was observed in Group B only. No differences in other evaluated parameters were found. These results seem to suggest that acromegalic patients considered cured on the basis of previous guidelines do not need a more intensive monitoring than patients who met the current criteria of disease control, supporting instead that the cut-off of 0.4 mcg/L might be too low for the currently used GH assay.

Original languageEnglish
Article number581594
JournalInternational Journal of Endocrinology
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

Guidelines
Acromegaly
Metabolome
Physiologic Monitoring
Insulin-Like Growth Factor I

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Reevaluation of acromegalic patients in long-term remission according to newly proposed consensus criteria for control of disease. / Verrua, Elisa; Ferrante, Emanuele; Filopanti, Marcello; Malchiodi, Elena; Sala, Elisa; Giavoli, Claudia; Arosio, Maura; Lania, Andrea Gerardo; Ronchi, Cristina Lucia; Mantovani, Giovanna; Beck-Peccoz, Paolo; Spada, Anna.

In: International Journal of Endocrinology, Vol. 2014, 581594, 2014.

Research output: Contribution to journalArticle

Verrua, Elisa ; Ferrante, Emanuele ; Filopanti, Marcello ; Malchiodi, Elena ; Sala, Elisa ; Giavoli, Claudia ; Arosio, Maura ; Lania, Andrea Gerardo ; Ronchi, Cristina Lucia ; Mantovani, Giovanna ; Beck-Peccoz, Paolo ; Spada, Anna. / Reevaluation of acromegalic patients in long-term remission according to newly proposed consensus criteria for control of disease. In: International Journal of Endocrinology. 2014 ; Vol. 2014.
@article{4af1dc13d6fc4942a55e15a5392ad1c9,
title = "Reevaluation of acromegalic patients in long-term remission according to newly proposed consensus criteria for control of disease",
abstract = "Acromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likely that a percentage of patients previously considered as cured might present postglucose GH nadir levels not adequately suppressed, with potential implications on management. This study explored GH secretion, as well as hormonal, clinical, neuroradiological, metabolic, and comorbid profile in a cohort of 40 acromegalic patients considered cured on the basis of the previous guidelines after a mean follow-up period of 17.2 years from remission, in order to assess the impact of the current criteria. At the last follow-up visit, in the presence of normal IGF-I concentrations, postglucose GH nadir was over 0.4 g/L in 11 patients (Group A) and below 0.4 g/L in 29 patients (Group B); moreover, Group A showed higher basal GH levels than Group B, whereas a significant decline of both GH and postglucose GH nadir levels during the follow-up was observed in Group B only. No differences in other evaluated parameters were found. These results seem to suggest that acromegalic patients considered cured on the basis of previous guidelines do not need a more intensive monitoring than patients who met the current criteria of disease control, supporting instead that the cut-off of 0.4 mcg/L might be too low for the currently used GH assay.",
author = "Elisa Verrua and Emanuele Ferrante and Marcello Filopanti and Elena Malchiodi and Elisa Sala and Claudia Giavoli and Maura Arosio and Lania, {Andrea Gerardo} and Ronchi, {Cristina Lucia} and Giovanna Mantovani and Paolo Beck-Peccoz and Anna Spada",
year = "2014",
doi = "10.1155/2014/581594g",
language = "English",
volume = "2014",
journal = "International Journal of Endocrinology",
issn = "1687-8337",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Reevaluation of acromegalic patients in long-term remission according to newly proposed consensus criteria for control of disease

AU - Verrua, Elisa

AU - Ferrante, Emanuele

AU - Filopanti, Marcello

AU - Malchiodi, Elena

AU - Sala, Elisa

AU - Giavoli, Claudia

AU - Arosio, Maura

AU - Lania, Andrea Gerardo

AU - Ronchi, Cristina Lucia

AU - Mantovani, Giovanna

AU - Beck-Peccoz, Paolo

AU - Spada, Anna

PY - 2014

Y1 - 2014

N2 - Acromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likely that a percentage of patients previously considered as cured might present postglucose GH nadir levels not adequately suppressed, with potential implications on management. This study explored GH secretion, as well as hormonal, clinical, neuroradiological, metabolic, and comorbid profile in a cohort of 40 acromegalic patients considered cured on the basis of the previous guidelines after a mean follow-up period of 17.2 years from remission, in order to assess the impact of the current criteria. At the last follow-up visit, in the presence of normal IGF-I concentrations, postglucose GH nadir was over 0.4 g/L in 11 patients (Group A) and below 0.4 g/L in 29 patients (Group B); moreover, Group A showed higher basal GH levels than Group B, whereas a significant decline of both GH and postglucose GH nadir levels during the follow-up was observed in Group B only. No differences in other evaluated parameters were found. These results seem to suggest that acromegalic patients considered cured on the basis of previous guidelines do not need a more intensive monitoring than patients who met the current criteria of disease control, supporting instead that the cut-off of 0.4 mcg/L might be too low for the currently used GH assay.

AB - Acromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likely that a percentage of patients previously considered as cured might present postglucose GH nadir levels not adequately suppressed, with potential implications on management. This study explored GH secretion, as well as hormonal, clinical, neuroradiological, metabolic, and comorbid profile in a cohort of 40 acromegalic patients considered cured on the basis of the previous guidelines after a mean follow-up period of 17.2 years from remission, in order to assess the impact of the current criteria. At the last follow-up visit, in the presence of normal IGF-I concentrations, postglucose GH nadir was over 0.4 g/L in 11 patients (Group A) and below 0.4 g/L in 29 patients (Group B); moreover, Group A showed higher basal GH levels than Group B, whereas a significant decline of both GH and postglucose GH nadir levels during the follow-up was observed in Group B only. No differences in other evaluated parameters were found. These results seem to suggest that acromegalic patients considered cured on the basis of previous guidelines do not need a more intensive monitoring than patients who met the current criteria of disease control, supporting instead that the cut-off of 0.4 mcg/L might be too low for the currently used GH assay.

UR - http://www.scopus.com/inward/record.url?scp=84920498939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920498939&partnerID=8YFLogxK

U2 - 10.1155/2014/581594g

DO - 10.1155/2014/581594g

M3 - Article

AN - SCOPUS:84920498939

VL - 2014

JO - International Journal of Endocrinology

JF - International Journal of Endocrinology

SN - 1687-8337

M1 - 581594

ER -